Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

320 Reports from FirstWord

   
  • Orphan Drug Market Access: Payer Insights on the Present and Future (2016)

    ...patient populations the cost was less of an issue. But with the orphan drug bill pushing 10% of drug spending to treat less than 1% of patients, hard questions are being asked and tough choices ... Read More

  • Market Access Impact: Myeloma (US)

    ...the way they prescribe 8 myeloma drugs. The results show that half of those treatments lose market share overall while the other half make small net gains. Find out why, and learn what your brand ... Read More

  • Colorectal Cancer KOL Insight 2016

    ...colorectal cancer (CRC). Some say novel therapies are the key. Others argue that a deeper understanding of the disease may have more of an impact by enabling personalised treatments. Find out how the treatment algorithm ... Read More

  • NPS+ Type 2 Diabetes Mellitus (US) 2016

    ...contenders – but which brands are the healthiest? What are the factors inspiring brand loyalty amongst US prescribers? And what can be done to convert detractors into promoters and, ultimately, improve market share? FirstView’s NPS+ ... Read More

  • NPS+ Type 2 Diabetes Mellitus (EU) 2016

    ...contenders – but which brands are the healthiest? What are the factors inspiring brand loyalty amongst Eurpean prescribers? And what can be done to convert detractors into promoters and, ultimately, improve market share? FirstView’s NPS+ ... Read More

  • The Healthcare Internet of Things: A Network of Opportunities for All (2016)

    ...Now our sector and others are seeing people and technology come together in incredibly exciting new ways, creating stronger connections and enabling continuous and productive conversations to take place in real time. The opportunities for ... Read More

  • Market Access Impact: Myeloma (EU5)

    ...the way they prescribe 8 myeloma drugs. The results show that half of those treatments lose market share overall while the other half make small net gains. Find out why, and learn what your brand ... Read More

  • Pharma Investment in Digital Health: Strategies for success

    ...control the rapidly growing digital health space.Internal investment in digital health technology may be too little and acquisitions of established players could be too late and costly. The operational benefits of digital health in terms ... Read More

  • Medical Affairs Reputations: Asthma/COPD (US)

    ...which three teams are competing for first place, which team scored lowest overall despite high performance and satisfaction ratings in key areas, and which company has 3 of the top 5 teams. All that and ... Read More

  • Medical Affairs Reputations: Asthma/COPD (EU)

    ...Find out which two teams are neck and neck for first place, whether teams representing fixed-dose combinations outperform those representing monotherapies, and which two key services most teams need to improve. All that and more ... Read More

  • The Real Value of Medical Affairs

    ...interactions would elevate MA to that elusive next level of engagement? Ultimately, what makes doctors want to talk to Medical Science Liaisons (MSLs)? The Real Value of Medical Affairs covers both sides of the equation ... Read More

  • The Future of Orphan Drugs

    ...research pressures and mounting payer scrutiny. It’s time to plan for the future. The Future of Orphan Drug provides a 360-degree scan of the horizon for rare disease therapies. Through primary research with leading industry ... Read More

  • NPS+ Rheumatoid Arthritis (US)

    ...brands are trouncing the competition, earning far and away the highest satisfaction and loyalty scores. Can rivals catch up, or are they stuck jockeying for position in the mid-market? Get the full story in FirstView ... Read More

  • What is Value in Healthcare: The payer definition

    ...view or wider health savings? With no consensus on the definition of value, how can industry meet the expectations of diverse and often sceptical US and European payers to secure market access? Informed by expert ... Read More

  • Hepatitis C: KOL Insight

    ...rapid pace. The focus has shifted to cure, and physicians now have more treatment options than ever. But which ones should they use? Key opinion leaders provide their views, as well as give their candid ... Read More

  • NPS+ Rheumatoid Arthritis (EU5)

    ...two long-time leaders continue to significantly outperform struggling rivals. Meanwhile, biosimilars are poised for huge market share gains if they can win over detractors. Get the full story in FirstView NPS+ Rheumatoid Arthritis (EU5). Request ... Read More

  • Market Access Impact: Multiple Sclerosis (US)

    ...of the 10 brands we surveyed eke out narrow market share gains while the other 5 lost out. Which barriers had the biggest impact? Are they the ones that helped the most prescribed brand gain ... Read More

  • The Future of Market Access

    ...other, more traditional activities, MA is pushing back the marketing boundaries. How is this multi-disciplined area evolving? And what must pharma companies do to stay ahead? FirstWord Dossier: The Future of Market Access examines the ... Read More

  • MAR T2DM (EU5)

    ...for how long? Competition is fierce, and a few small improvements could vault any number of teams into top spot. Find out, and see how your team measures up, in Medical Affairs Reputations: T2DM (EU5). ... Read More

  • Chronic Lymphocytic Leukaemia: KOL Insight

    ...up? Will Gazyva’s/Gazyvaro’s superior efficacy compared to Rituxan/MabThera influence prescribing decisions? How will familiarity, convenience and tolerability influence Imbruvica’s continued uptake? What pipeline therapies do KOLs have their eyes on? Do KOLs predict a significant ... Read More

  • Market Access Impact: Multiple Sclerosis (EU5)

    ...barriers helped 6 of the 10 brands we surveyed eke out narrow market share gains while the other 4 lost out. Which barriers had the biggest impact? Are they the ones that caused the least ... Read More

  • NSCLC: KOL Insight

    ...sort out what the results mean for Opdivo, and whether Keytruda will become the first-line PD-1/L1 inhibitor. Based on interviews with 12 key opinion leaders (KOLs), the report covers 13 marketed drugs and 9 in ... Read More

  • Measuring Marketing Channel Effectiveness

    ...so difficult to agree? A plethora of channels, target segments and technological challenges all add complexity and hamper decision-making clarity. This new report delves below the surface to uncover exactly how MCM can be measured ... Read More

  • Patient Assistance Programs

    ...sceptical, seeing PAPs as a cynical ploy by Pharma to buy market share and support drug prices. This report explores the patient benefits, operational challenges and attitudes to, and the future for, PAPs through the ... Read More

  • MAR T2DM (US)

    ...(T2DM) market. Are they delivering the services doctors need most, or are they simply more active than the rest of the pack? Find out, and see how your team measures up, in Medical Affairs Reputations: ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook